HK Stock MarketDetailed Quotes

02616 CSTONE PHARMA-B

Watchlist

2.770
+0.070+2.59%

Market Closed Feb 17 16:08 CST

3.56BMarket Cap-22.89P/E (TTM)

CSTONE PHARMA-B Stock Forum

Moomoo AI

Mar 15, 2024 17:45

CStone Pharmaceuticals' lower P/S ratio is due to its perceived limited future growth. Analysts' inferior revenue outlook contributes to its low P/S, making a significant share price rise unlikely soon.

CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%

Moomoo AI

Jan 18, 2024 16:36

CStone Pharmaceuticals' low P/S ratio is due to its poor revenue outlook. The market anticipates limited growth, paying less for the stock. These conditions form a barrier for the share price.

Why Investors Shouldn't Be Surprised By CStone Pharmaceuticals' (HKG:2616) 25% Share Price Plunge

Bamboo Works

Dec 22, 2023 01:06

Columns HBM gets health boost from drug licensing deals

HBM gets health boost from drug licensing deals
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...

Moomoo AI

Dec 4, 2023 17:32

The company's lack of profit over the last year prompts caution despite recent insider purchase showing confidence. Caution urged before investing in CStone Pharmaceuticals, despite insiders seeing potential value.

Insider Buyers At CStone Pharmaceuticals Likely Disappointed With 16% Slide

JulianMackie

Oct 21, 2021 02:24

$CSTONE PHARMA-B (02616.HK)$
Clinical approvals continue to be obtained. That's not good for the market. It becomes a bad day. That means the company will continue to burn cash. After entering shenzhen-Hong Kong stock connect, trading volume is even more depressed. Cornerstones become stepping stones. There was no agency to recommend it. Share prices have given up all this year's gains. This is cstone's darkest hour.